0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ALK-1

ALK-1

ALK-1 Molecule Information

Name:Activin receptor-like kinase 1
Target Synonym:TGF-B superfamily receptor type I;ACVRLK1 ;Activin receptor-like kinase 1;ALK-1;ACVRL1;ALK1;TSR-I;Serine/threonine-protein kinase receptor R3;SKR3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase ?

ALK-1 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
AL1-H5227 Human Human ALK-1 / ACVRL1 Protein, His Tag
AL1-H5227-structure
AL1-H5227-sds

ALK-1 Molecule Synonym Name

ACVRL1,ACVRLK1,ALK-1,HHT,HHT2,ORW2,SKR3,TSR-I

ALK-1 Molecule Background

Serine/threonine-protein kinase receptor R3 is an enzyme that in humans is encoded by the ALK1 gene. ALK1 is a receptor in the TGF beta signaling pathway. ALK1 protein is a receptor in the TGF beta signaling pathway. It plays an important role in vascular development, remodeling, and pathologic angiogenesis, play a role in stabilizing angiogenic vessels and contribute to resistance to anti-VEGF therapies, ALK1 blockade may represent an effective therapeutic opportunity complementary to the current antiangiogenic modalities in the clinic. Recently, researcher found that, ALK1-Fc inhibited BMP9-mediated Id-1 expression in human umbilical vein endothelial cells and inhibited cord formation by these cells on a Matrigel substrate, in a chick chorioallantoic membrane assay, ALK1-Fc reduced vascular endothelial growth factor-, fibroblast growth factor-, and BMP10-mediated vessel formation, and ALK1-Fc treatment reduced tumor burden in mice receiving orthotopic grafts of MCF7 mammary adenocarcinoma cells.

ALK-1 References

ALK-1 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Dalantercept ACE-041 Phase Ⅱ Acceleron Renal cell carcinoma, Solid tumours, Multiple myeloma (MM), Hepatocellular carcinoma (HCC), Head and neck cancer Details
Ascrinvacumab GT-90001; PF-03446962; PF-3446962; PF-3-446-962 Phase Ⅱ Pfizer, Duke University Medical Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Suzhou Kintor Pharmaceuticals Age-related macular degeneration (AMD), Liver cancer, Cancer Details

This web search service is supported by Google Inc.

totop